Clinical trial Recruiting at 6 sites Interventional Ages 15 to 24

Combining interventions to address HIV in Nigerian youth

Official title: Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness/Implementation Hybrid Study: Aim 2

Run by Northwestern University · NCT06880224 · Data updated 2026-11-12

This study is testing two different ways to help young people in Nigeria, aged 15-24, get tested for HIV and stick to their treatment to manage the virus better.

Quick facts

Study typeInterventional
Ages15 Years to 24 Years
SexAll
Enrollment500 (estimated)
SponsorNorthwestern University
Academic / other
Locations6 sites (Uyo, Akwa Ibom State and 5 other locations)
StatusRecruiting
StartedFebruary 1, 2025
Main results expectedAugust 31, 2028
Study endsAugust 31, 2028
Registry record updatedApril 8, 2026
Trial IDNCT06880224 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include males aged 15-24 who are either at risk of HIV infection or newly diagnosed with HIV.

Probably not a fit

Patients who are not within the age range of 15-24 or who are not HIV-positive will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates two combination interventions aimed at addressing HIV among youth aged 15-24 in Nigeria. The first intervention focuses on HIV case finding and linkage to care, particularly targeting young men who have sex with men, while the second intervention is a randomized controlled trial assessing medication adherence and viral suppression among newly diagnosed HIV patients. Both interventions incorporate mobile health (mHealth) strategies and peer navigation to enhance effectiveness. The study will run for 48 weeks and aims to improve HIV testing, treatment initiation, and adherence.

Why it matters

Potential benefit: If successful, this study could significantly improve HIV detection and treatment outcomes among Nigerian youth.

How similar studies have gone: Other studies have shown success with similar combination intervention approaches in addressing HIV, indicating potential for positive outcomes in this study.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

HIV Case Finding Intervention:

* Aged 15 to 24
* Male birth sex of any current gender identity
* Understand basic English, Yoruba, Hausa, Igbo or Pidgin English For the PrEP component, must also be HIV-negative

HIV Treatment Intervention:

* Aged 15 to 24
* HIV seropositive
* Initiating ART for the first time at a Clinical Research Performance Site (CRPS) clinic or satellite clinic
* Understand basic English, Yoruba, Hausa, Igbo or Pidgin English
* Intention to remain a CRPS patient during follow-up

Exclusion Criteria:

* Unable to provide consent
* No parental permission if aged 15 and not emancipated

Where it's running

  • University of Uyo Teaching Hospital
    Uyo, Akwa Ibom State, Nigeria
    Recruiting
  • Federal Medical Center
    Makurdi, Benue State, Nigeria
    Recruiting
  • Taraba State Specialist Hospital
    Jalingo, Taraba State, Nigeria
    Recruiting
  • University of Nigeria Teaching Hospital
    Enugu, Nigeria
    Recruiting
  • Aminu Kano Teaching Hospital
    Kano, Nigeria
    Recruiting
  • Lagos University Teaching Hospital
    Lagos, Nigeria
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.